Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Lung Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplasms 1Melanoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Brain Neoplasms 1Brain Diseases 1Astrocytoma 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × Adjuvants, Immunologic × Clear all
NCT01290692 2023-07-03

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

TVAX Biomedical

Phase 2 Completed
14 enrolled 11 charts
CNS

Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms, Nervous System Diseases, Nervous System Neoplasms, Central Nervous System Neoplasms

NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡